FrancophonIA/ELRC3.0 huggingface dataset:
English: Very rare: moniliasis (gastro-intestinal), pancreatitis.
Maltese: Rari ħafna: moniliasi (gastro-intestinali), pankreatite.
English: Rare: pseudomembranous colitis, moniliasis (oral).
Maltese: Rari: kolite psewdomembranuża, moniliasi (orali).
English: Pack sizes: 1.5 10 or 20 vials.
Maltese: Daqsijiet tal-pakketti: 1, 5, 10 jew 20 kunjetti
English: The active substance is ciprofloxacin lactate.
Maltese: Is-sustanza attiva hi ciprofloxacin lactate.
English: Hydrochloric acid (E 507) for pH adjustment Water for injections
Maltese: Hydrochloric acid (E 507) għal aġġustament tal-pH Water for injections
English: This medicinal product is authorised in the Member States of EEA under the following names: Austria - Ciprofloxacin Hikma 200mg/100ml Infusionslösung Germany - Ciprofloxacin Hikma 200mg/100ml Lösung zur Intravenösen Anwendung Ireland - Ciprofloxacin Hikma 200mg/100ml Solution for Infusion Italy - Ciprofloxacin Hikma 200mg/100ml Soluzione per Infusione Endovenosa United Kingdom - Ciprofloxacin Hikma 200mg/100ml Solution for Infusion The Netherlands - Ciprofloxacine Hikma 200mg/100ml Oplossing voor Intraveneuze Infusie
Maltese: Dan il-prodott medicinali huwa awtorizzat fl-istati membri ta' l-EEA b'dawn l-ismijiet: Awstrija - Ciprofloxacin Hikma 200 mg/100 ml Infusionslösung Ġermanja - Ciprofloxacin Hikma 200 mg/100 ml Lösung zur Intravenösen Anwendung Irlanda - Ciprofloxacin Hikma 200 mg/100 ml Solution for Infusion Italja - Ciprofloxacin Hikma 200 mg/100 ml Soluzione per Infusione Endovenosa Renju Unit - Ciprofloxacin Hikma 200 mg/100 ml Solution for Infusion Olanda - Ciprofloxacine Hikma 200 mg/100 ml Oplossing voor Intraveneuze Infusie
English: Staphylococcus haemolyticus Gram-negative aerobes
Maltese: Staphylococcus epidermidis Staphylococcus haemolyticus Aerobi Gram-negattivi
English: Gastrointestinal tract:
Maltese: Passaġġ gastrointestinali:
English: Very rare: erythema nodosum, erythema multiforme (minor), Stevens-Johnson syndrome, epidermal necrolysis (Lyell Syndrome), petechia.
Maltese: Rari ħafna: eritema nodosum, eritema multiforme (minuri), sindrome ta' Stevens-Johnson, nekrolisi epidermali (sindrome ta' Lyell), tbenġil.
English: Photosensibility:
Maltese: Sensittività eċċessiva:
English: The maximum daily dose is 1200 mg.
Maltese: Id-doża massima ta' kuljum hi ta' 1200 mg.
English: Antiperistaltics are contraindicated.
Maltese: L-antiperistaltiċi huma kontra-indikati.
English: Adverse reactions have been reported in 5-14% of patients receiving ciprofloxacin.
Maltese: Reazzjonijiet avversi kienu irrappurtat f'5-14% tal-pazjenti li kienu qed jirċievu ciprofloxacin.
English: • phenytoin (used to treat epilepsy).
Maltese: • phenytoin (jintuża għall-kura ta' l-epilessija).
English: This relatively high distribution volume indicates an effective tissue and fluid penetration.
Maltese: Dan il-volum tad-distribuzzjoni relattivament għoli jindika penetrazzjoni effettiva tal-fluwidu fit-tessut.
English: Development of resistance to ciprofloxacin and other fluoroquinolones has been observed in staphylococci, especially methicillinresistant S. aureus, P. aeruginosa, E.coli and E. faecalis (see the sensitivity table).
Maltese: L-iżvilupp tar-reżistenza għal ciprofloxacin u fluoroquinolones oħrajn kien osservat fi staphylococci, speċjalment f'S. aureus li hu reżistenti għal methicillin, P. aeruginosa, E.coli u E. faecalis (ara t-tabella tas-sensittività).
English: Pharmacotherapeutic group: Antibacterial quinolones, ATC code: J01MA02
Maltese: Kategorija farmakoterapewtika: quinolones anti-batteriċi, Kodiċi ATC:
English: • glibenclamide (used to treat diabetes).
Maltese: • glibenclamide (jintuża għall-kura tad-dijabete).
English: For information on mixing with other solutions: see sections 6.2 and 6.6.
Maltese: Għal informazzjoni dwar it-taħlit ma' soluzzjonijiet oħrajn: ara sezzjonijiet 6.2 u 6.6.
English: Uncommon: pruritis, papillo-macular rash, urticaria.
Maltese: Mhux komuni: ħakk, raxx papillo-makulari, urtikarja.
English: According to EUCAST the following breakpoints for aerobic bacteria have been defined for ciprofloxacin:
Maltese: Skond l-EUCAST il-breakpoints li ġejjin għal batterji aerobiċi kienu definiti għal ciprofloxacin:
English: STATEMENT OF ACTIVE SUBSTANCE(S) 1 ml solution for infusion contains : Ciprofloxacin lactate equivalent to 2 mg ciprofloxacin.
Maltese: DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA 1 ml soluzzjoni għall-infużjoni fiha: Ciprofloxacin lactate ekwivalenti għal 2 mg ta' ciprofloxacin.
English: Uncommon: eosinophilia, leukopenia.
Maltese: Mhux komuni: eosinofilja, lewkopenja.
English: In steady-state conditions the apparent distribution volume of ciprofloxacin is situated between 1,7 and 2,7 l/kg.
Maltese: Fil-kundizzjonijiet ta' l-istat fiss, il-volum apparenti tad-distribuzzjoni ta' ciprofloxacin ikun bejn 1.7 u 2.7 l/kg.
English: Lactic acid (E270), sodium chloride, hydrochloric acid (E507) and water for injection.
Maltese: LISTA TA' SUSTANZI MHUX ATTIVI Lactic acid (E270), sodium chloride, hydrochloric acid (E507) u ilma għall-injezzjonijiet.
English: Ciprofloxacin lactate equivalent to 2 mg ciprofloxacin.
Maltese: Ciprofloxacin lactate ekwivalenti għal 2 mg ta' ciprofloxacin.
English: It is also effective against Gram-positive organisms, such as staphylococci and streptococci.
Maltese: Hu effettiv ukoll kontra organiżmi Gram-pożittivi bħal staphylococci u streptococci.
English: Ciprofloxacin Hikma is compatible with isotonic sodium chloride solution, Ringer's solution, Ringer's lactate solution, 50 mg/ml (5 %) or 100 mg/ml (10 %) glucose solution and 50 mg/ml (5 %) glucose solution with 2.25 mg/ml (0.225 %) or 4.5 mg/ml (0.45 %) sodium chloride solution and 10% fructose solution.
Maltese: Ciprofloxacin Hikma hu kompatibbli ma' soluzzjoni isotonika ta' sodium chloride, soluzzjoni ta' Ringer, soluzzjoni ta' Ringer lactate, soluzzjoni ta' 50 mg/ml (5%) jew 100 mg/ml (10%) glucose u soluzzjoni ta' 50 mg/ml (5%) glucose ma' 2.25 mg/ml (0.225%) jew soluzzjoni ta' 4.5 mg/ml (0.45%) ta' sodium chloride u soluzzjoni ta' 10% fructose.
English: The peak plasma concentration is reached 0.5 - 2 hours after taking 50 - 1000 mg p.o. and varies from 0.3 - 5.9 mg/l.
Maltese: Il-konċentrazzjoni massima fil-plażma tintlaħaq wara 30 minuta sa sagħtejn wara t-teħid ta' 50-1000 mg p.o. u tvarja bejn 0.3-5.9 mg/l.
English: • probenecid (used to treat gout).
Maltese: • probenecid (jintuża għall-kura tal-gotta).
English: Very rare: haemolytic anaemia, pancytopenia, agranulocytosis.
Maltese: Rari ħafna: anemija emolitika, panċitopenja, agranuloċitosi.
English: Ciprofloxacin Hikma is compatible with physiological sodium chloride solution, Ringer's solution, Ringer's lactate solution, 50 mg/ml (5 %) or 100 mg/ml (10 %) glucose solution and 50 mg/ml (5 %) glucose solution with 2.25 mg/ml (0.225 %) or 4.5 mg/ml (0.45 %) sodium chloride solution and 10% fructose solution.
Maltese: Ciprofloxacin Hikma hu kompatibbli ma' soluzzjoni fiżjoloġika ta' sodium chloride, soluzzjoni ta' Ringer, soluzzjoni lactate ta' Ringer, soluzzjoni ta' 50 mg/ml (5%) jew 100 mg/ml (10%) glucose u soluzzjoni ta' 50 mg/ml (5%) glucose ma' 2.25 mg/ml (0.225%) jew soluzzjoni ta' 4.5 mg/ml (0.45%) ta' sodium chloride u soluzzjoni ta' 10% fructose.
English: As a result of its mechanism of action, ciprofloxacin does not show cross-resistance with other important, chemically different groups of substances such as beta-lactam antibiotics, aminoglycosides, tetracyclines, macrolides and polypeptides, sulphonamides, trimethoprim and nitrofurantoine.
Maltese: Bħala riżultat tal-mekkaniżmu ta' l-azzjoni tiegħu, ciprofloxacin ma jurix reżistenza inkroċjata ma' gruppi oħrajn ta' sustanzi importanti li huma kimikament differenti, bħal antibijotiċi beta-lactam, aminoglycosides, tetracyclines, macrolides u polypeptides, sulphonamides, trimethoprim u nitrofurantoine.
English: Do NOT use Ciprofloxacin Hikma:
Maltese: TUŻAX Ciprofloxacin Hikma:
English: Clear, colourless to slightly yellow solution pH of the solution: 3.9 - 4.5
Maltese: Soluzzjoni ċara, bla kulur jew ta' kulur kemm kemm isfar pH tas-soluzzjoni: 3.9-4.5
English: Rare: leukopenia (granulocytopenia), anaemia, leukocytosis, altered prothrombin values, thrombocytopenia, thrombocytemia (thrombocytosis).
Maltese: Rari: lewkopenja (granuloċitopenja), anemija, lewkoċitosi, valuri mibdulin tal-prothrombin, tromboċitopenja, tromboċitemija (tromboċitosi).
English: Rare: acute renal failure, impaired renal function, vaginal moniliasis, haematuria, crystalluria, interstitial nephritis.
Maltese: Rari: kollass akut tal-kliewi, indeboliment fil-funzjoni tal-kliewi, moniliasi vaġinali, ematurja, kristallurja, nefrite interstizjali.
English: Very rare in less than 1 in 10,000 patients, including isolated reports
Maltese: Rari ħafna f'inqas minn 1 f'kull 10,000 pazjent, li jinkludu rapporti iżolati
English: Part of it is converted into desethylene-, sulpho-, oxoand formylciprofloxacin.
Maltese: Parti minnu tinbidel f'desethylene-, sulpho-, oxou formylciprofloxacin.
English: The ciprofloxacin concentration in the sputum consists of 50-70% of the serum concentration.
Maltese: Il-konċentrazzjoni ta' ciprofloxacin fl-isputum tikkonsisti f'50-70% tal-konċentrazzjoni fis-serum.
English: Ciprofloxacin Hikma is an antibiotic.
Maltese: Ciprofloxacin Hikma hu antibijotiku.
English: Eye disorders: Rare: disturbed vision, diplopia, chromatopsia.
Maltese: Rari: disturb fil-vista, diplopja, kromatopsija.
English: Ciprofloxacin is effective in vitro against a large number of Gram-negative aerobic bacteria including P. aeruginosa.
Maltese: Ciprofloxacin hu effettiv in vitro kontra numru kbir ta' batterji aerobiċi Gram-negattivi li jinkludu P. aeruginosa.
English: Side effects have been reported in 5-14% of patients receiving ciprofloxacin.
Maltese: Effetti sekondarji kienu irrappurtati f'5-14% tal-pazjenti li kienu qed jirċievu ciprofloxacin.
English: In juvenile and prenatal animals exposed to quinolones effects on immature cartilage have been observed (see section 5.3).
Maltese: F'annimali żgħar u ta' qabel it-twelid esposti għall-effetti ta' quinolones, kienu osservati effetti fuq il-kartilaġni immatura (ara sezzjoni 5.3).
English: • methotrexate (used to treat cancer or suppress the immune system).
Maltese: • methotrexate (jintuża għall-kura tal-kanċer jew biex irażżan is-sistema immuni).
English: Chemical and physical in-use stability has been demonstrated immediately after dilution, after 24 hours at 2-8°C and after 24 hours at room temperature.
Maltese: L-istabbiltà kimika u fiżika waqt l-użu ntweriet immedjatament wara d-dilwizzjoni, wara 24 siegħa f'temperatura ta' 2-8°C u wara 24 siegħa fit-temperatura tal-kamra.
English: Excipient 15.4 mmol (354 mg) sodium per 100 ml of solution for infusion For a full list of excipients, see section 6.1.
Maltese: 4 mmol (354 mg) ta' sodium f'kull 100 ml ta' soluzzjoni għall-infużjoni Għal-lista kompleta ta' sustanzi mhux attivi, ara sezzjoni 6.1.
English: Uncommon (≥1/1 000 to <1/100)
Maltese: Mhux komuni (≥1/1 000 sa <1/100)
English: 1 ml solution for infusion contains:
Maltese: 1 ml soluzzjoni għall-infużjoni fiha:
English: Musculoskeletal and connective tissue disorders:
Maltese: Disturbi muskolu-skeltrali u tal-connective tissue
English: • myastenia gravis (a particular type of muscle weakness).
Maltese: • myastenia gravis (tip partikulari ta' dgħjufija fil-muskoli).
English: E. coli multi-resistant Providencia spp.
Maltese: E. coli multi-reżistenti
English: Very rare: increment of amylase/lipase levels.
Maltese: Rari ħafna: żieda fil-livelli ta' amylase/lipase.
English: Infections and infestations: Uncommon: moniliasis
Maltese: Mhux komuni: moniliasi
English: • glucose-6-phosphate dehydrogenase defect (hereditary disease of the red blood cells based on a defect in an enzyme).
Maltese: • difett ta' glucose-6-phosphate dehydrogenase (marda ereditarja taċ-ċelluli ħomor tad-demm ibbażata fuq difett f'enzima).
English: In case of very severe infections the dose can be increased up to a maximum daily dose of 1200 mg (400 mg thrice daily).
Maltese: F'każ ta' infezzjonijiet severi ħafna, id-doża tista' tiżdied sa doża massima ta' kuljum ta' 1200 mg (400 mg tliet darbiet kuljum).
English: Estrada do Rio da Mó n.º 8, 8A e 8B - Fervença 2705-906 Terrugem SNT Portugal
Maltese: Estrada do Rio da Mó n.º 8, 8A e 8B - Fervença 2705-906 Terrugem SNT Portugall
English: • severe and continuous diarrhoea during treatment, possibly with blood and mucus.
Maltese: • dijarea kontinwa u severa matul il-kura, possibbilment bid-demm u bil-mukus.
English: Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e.g. theophylline, clozapine, tacrine, ropinirol, tizanidine).
Maltese: Ciprofloxacin jinibixxi CYP1A2 u għaldaqstant jista' jikkawża żieda fil-konċentrazzjoni fis-serum ta' sustanzi li jingħataw fl-istess ħin li jkunu metabolati minn din l-enzima (eż. theophylline, clozapine, tacrine, ropinirol, tizanidine).
English: Because ciprofloxacin has some activity against Mycobacterium tuberculosis, false-negative cultures may occur when the specimens are obtained during ciprofloxacin treatment.
Maltese: Minħabba li ciprofloxacin għandu xi attività kontra Mycobacterium tuberculosis, kulturi foloz-negattivi jistgħu jseħħu meta l-kampjuni jinkisbu waqt il-kura b'ciprofloxacin.
English: Estrada do Rio da Mó, 8, 8A e 8B - Fervença 2705-906 Terrugem SNT Portugal
Maltese: Estrada do Rio da Mó, 8, 8A e 8B - Fervença 2705-906 Terrugem SNT Portugall
English: • theophylline (used to treat asthma), clozapine (used to treat schizophrenia), tacrine (used to treat symptoms of Alzheimer´s disease), ropinirol (used to treat Parkinson disease) and tizanidine (used to treat muscle spasms).
Maltese: • theophylline (jintuża għall-kura ta' l-ażżma), clozapine (jintuża għall-kura ta' l-iskiżofrenja), tacrine (jintuża għall-kura tas-sintomi tal-marda Alzheimer´s), ropinirol (jintuża għall-kura tal-marda ta' Parkinson) u tizanidine (jintuża għall-kura ta' spażmi tal-muskoli).
English: Ciprofloxacin may cause an exacerbation of Myastenia gravis symptoms.
Maltese: Ciprofloxacin jista' jikkawża aggravament tas-sintomi ta' Myastenia gravis.
English: ≤ 1 µg/ml for susceptible, > 1 µg/ml for resistant; - H. influenza and M. catarrhalis ≤ 0.5 µg/ml for susceptible, > 0.5 µg/ml for resistant.
Maltese: - Staphylococcus spp. ≤ 1 µg/ml għas-suxxettibbli, > 1 µg/ml għar-reżistenti; - H. influenza u M. catarrhalis ≤ 0.5 µg/ml għas-suxxettibbli, > 0.5 µg/ml għar-reżistenti.
English: A larger number of metabolites after oral administration indicates some degree of first-pass metabolism, mainly forming sulphociprofloxacin.
Maltese: Numru ikbar ta' metaboliti wara l-għoti mill-ħalq jindika xi grad ta' metaboliżmu first-pass, u primarjament jiffurmaw sulphociprofloxacin.
English: The elimination half-life of ciprofloxacin after single or multiple oral dosage is between 3.4 and 6.9 hours.
Maltese: Il-half-life ta' l-eliminazzjoni ta' ciprofloxacin wara doża waħda jew dożi multipli hi ta' bejn 3.4 u 6.9 sigħat.
English: Others:
Maltese: Taqsiriet:
English: The solution for infusion should be administered over an infusion period of 60 minutes.
Maltese: Is-soluzzjoni għall-infużjoni għandha tingħata fuq perjodu ta' infużjoni ta' 60 minuta.
English: • patients with a hypersensitivity to ciprofloxacin, quinoline carboxylic acid derivatives or to any of the excipients
Maltese: • pazjenti b'sensittività eċċessiva għal ciprofloxacin, derivattivi ta' quinoline carboxylic acid jew xi sustanzi mhux attivi
English: • caffeine (used as a stimulant), pentoxifylline (used to treat circulatory disorders in the limbs) and mexiletine (used to treat irregular heart beat).
Maltese: • caffeine (użata bħala stimulant), pentoxifylline (jintuża għall-kura ta' mard ċirkolatorju fid-dirgħajn/riġlejn) u mexiletine (jintuża għall-kura ta' taħbit irregolari tal-qalb).
English: In patients with a creatinine clearance in the range 31 - 60 ml/minute/1.73 m2 or a serum creatinine concentration in the range 124 - 174 µmol/l, the maximum daily intravenous dose is 800 mg.
Maltese: F'pazjenti bi tneħħija tal-kreatinina fil-medda 31-60 ml/minuta/1.73 m2 jew konċentrazzjoni tal-creatine fis-serum fil-medda ta' 124-174 µmol/l, id-doża massima ta' kuljum ġol-vina hi ta' 800 mg.
English: The plasma protein binding of ciprofloxacin is situated between 16% and 28% and is not dependent on the concentration and pH (determined by means of ultrafiltration).
Maltese: It-twaħħil ta' ciprofloxacin mal-proteini fil-plażma hu ta' bejn 16% u 28%, u ma jiddependix fuq il-konċentrazzjoni u fuq il-pH (ikun stabbilit permezz ta' ultrafiltrazzjoni).
English: Central nervous system:
Maltese: Is-sistema nervuża ċentrali
English: ≤ 1 µg/ml for susceptible, > 1 µg/ml for resistant; - S. pneumonia ≤ 0.125 µg/ml for susceptible, > 2 µg/ml for resistant; - Staphylococcus spp.
Maltese: - Acinetobacter spp. ≤ 1 µg/ml għas-suxxettibbli, > 1 µg/ml għar-reżistenti; - S. pneumonia ≤ 0.125 µg/ml għas-suxxettibbli, > 2 µg/ml għar-reżistenti;
English: - The literature provided by the applicant support a dose of 200 - 400 mg twice daily in the treatment of complicated urinary tract infections and a maximum adult daily dose of 400 mg three times daily.
Maltese: - Il-letteratura pprovduta mill-applikant tappoġġja doża ta' 200 - 400 mg darbtejn kuljum fittrattament ta' infezzjonijiet komplikati fil-pajp ta' l-awrina u doża massima ta' 400 mg tliet darbiet kuljum u
English: Commonly susceptible species Gram-negative aerobe species Citrobacter spp.
Maltese: Speċi li huma suxxettibbli b'mod komuni Speċi ta' aerobi Gram-negattivi Citrobacter spp.
English: Most frequent adverse effects involve the gastro-intestinal tract and the central nervous system.
Maltese: Il-biċċa l-kbira ta' l-effetti avversi frekwenti jinvolvu l-passaġġ gastro-intestinali u s-sistema nervuża ċentrali.
English: Intravenous use 200mg/100ml
Maltese: Preżentazzjoni ta' 200 mg/100 ml: 100 ml
English: Very rare: asthenia, a transient impairment of kidney function to transient renal failure, photosensitivity (see Section 4.4).
Maltese: Rari ħafna: astenja, indeboliment temporanju tal-funzjoni tal-kliewi sa kollass temporanju tal-kliewi, sensittività għad-dawl (ara sezzjoni 4.4).
English: An overdose of 12 g has been reported to lead to mild symptoms of toxicity.
Maltese: Doża eċċessiva ta' 12 g kienet irrappurtata li twassal għal sintomi ħfief ta' tossiċità.
English: Symptoms of overdose may include dizziness, tremor, headaches, tiredness, seizures, hallucinations, confusion, gastrointestinal upset, liver and kidney abnormalities, crystalluria, haematuria.
Maltese: Sintomi ta' doża eċċessiva jistgħu jinkludu sturdament, rogħda, uġigħ ta' ras, għeja, puplesiji, alluċinazzjonijiet, konfużjoni, problemi gastrointestinali, anormalitajiet fil-fwied u fil-kliewi, kristallurja, ematurja.
English: UK
Maltese: Olanda
English: On concurrent administration of ciprofloxacin and caffeine or pentoxifylline (oxpentifylline), raised serum concentrations of these xanthine derivatives were reported.
Maltese: Wara l-għoti fl-istess ħin ta' ciprofloxacin u caffeine jew pentoxifylline (oxpentifylline), kienu rrappurtati żiediet fil-konċentrazzjonijiet ta' dawn id-derivattivi ta' xanthine fis-serum.
English: Very rare: parosmia (impaired smell), anosmia (usually reversible after interruption), grand mal convulsion, abnormal (unstable) gait, intracranial hypertension, ataxia, hyperesthesia, hypertonia.
Maltese: Rari ħafna: parosmija (indeboliment fix-xamm), anosmija (normalment riversibbli wara linterruzzjoni), konvulżjoni grand mal, mod anormali ta' kif timxi (mixi instabbli), pressjoni tad-demm intrakranjali għolja, atassja, iperestesija, ipertonija.
English: LABELLING
Maltese: Applikant
English: - Enterobacteriaceae: ≤ 0.5 µg/ml for susceptible, > 1 µg/ml for resistant; - Pseudomonas spp.
Maltese: - Enterobacteriaceae: ≤ 0.5 µg/ml għas-suxxettibbli, > 1 µg/ml għar-reżistenti;
English: Ciprofloxacin inhibits DNA-gyrase, resulting in inhibition of DNA synthesis.
Maltese: Ciprofloxacin u fluoroquinolones oħrajn jistgħu jikkawżaw sensittività għad-dawl.
English: In this leaflet:
Maltese: Mod ta' azzjoni:
English: NL
Maltese: MEMBRI
English: In very rare cases ventricular arrhythmia, QT interval prolongation and torsades de pointes have been reported.
Maltese: F'każijiet rari ħafna, arritmija ventrikulari, titwil fl-intervall tal-QT u torsades de pointes kienu rrappurtati.
English: Ciprofloxacin is a quinolone effective in vitro against a large number of Gram-negative aerobic bacteria as well as against some Gram-positive organisms.
Maltese: Ciprofloxacin hu quinolone effettiv in vitro kontra numru kbir ta' batterji arobiċi Gram-negative kif ukoll kontra numru kbir ta' organiżmi Gram-positive.
English: • If Ciprofloxacin Hikma and tizanidine (used to treat muscle spasms) are given at the same time.
Maltese: • Jekk Ciprofloxacin Hikma u tizanidine (jintużaw għall-kura ta' spażmi fil-muskoli) jingħataw flistess ħin.
English: In patients with severely impaired renal function (creatinine clearance <30 ml/min) the elimination half-life may be prolonged by a factor of 2.
Maltese: F'pazjenti b'indeboliment sever fil-funzjoni tal-kliewi (tneħħija tal-creatine ta' <30 ml/min), il-half-life ta' l-eliminazzjoni tista' titwal b'fattur ta' 2.
English: Premedicants
Maltese: Pre-medikanti
English: • temporary pain and inflammation of the tendons, in particular of the Achilles tendon.
Maltese: • uġigħ temporanju u infjammazzjoni tat-tendini, b'mod partikulari tat-tendine ta' Achilles.
English: Renal and urinary system:
Maltese: Is-sistema tal-kliewi u dik urinarja:
English: Rare in more than 1 in 10,000 patients, but less than 1 in 1,000 patients
Maltese: Rari f'iktar minn 1 f'kull 10,000 pazjent, iżda f'inqas minn 1 f'kull 1,000 pazjent
English: Rare: oedema (peripheral, angio, facial), allergic reaction, drug fever, anaphylactoid (anaphylactic) reaction.
Maltese: Rari: edema (periferali, anġjo, tal-wiċċ), reazzjoni allerġika, deni minħabba l-mediċina, reazzjoni anafilattojdi (anafilattika)
English: The treatment of acute pulmonary infections in children and adolescents with cystic fibrosis will take 10-14 days.
Maltese: Il-kura ta' infezzjonijiet pulmonari akuti fit-tfal u fl-adolexxenti b'fibrożi ċistika ser tieħu bejn 10 u 14-il jum.
English: dosage the elimination half-life is between 3 - 4.6 hours.
Maltese: Wara doża waħda jew dożi multipli minn ġol-vina, il-half-life ta' l-eliminazzjoni hi ta' bejn 3 u 4.6 sigħat.
English: Ciprofloxacin Hikma is contraindicated in:
Maltese: Ciprofloxacin Hikma hu kontra-indikat f':
English: • complicated urinary tract infections
Maltese: • infezzjonijiet kumplikati tal-passaġġ urinarju
English: Uncommon: vomiting, dyspepsia, flatulence, anorexia, abdominal pain.
Maltese: Mhux komuni: rimettar, dispepsja, gass, anoreksja, uġigħ addominali.
English: Rare: photosensibility, erythema multiforme and erythema nodusum.
Maltese: Rari: sensittività għad-dawl, eritema multiforme u eritema nodusum.
English: Transferable plasmid-mediated quinolone resistance associated with qnr has been detected in quinolone-resistant clinical strains of E.coli and Klebsiella spp.
Maltese: Reżistenza trasferibbli għal quinolone medjata mill-plasmid, assoċjata ma' qnr kienet osservata f'razez ta' E.coli u Klebsiella spp. li kienu klinikament reżistenti għal quinolone.
English: Each vial of 100 ml contains 200 mg of ciprofloxacin.
Maltese: Kull kunjett b'100 ml fih 200 mg ta' ciprofloxacin.
English: Rare: icterus, cholestatic icterus, liver cell necrosis.
Maltese: Rari: ikterus, ikterus kolestatiku, nekrosi taċ-ċelluli tal-fwied.
English: IE
Maltese: Billi
English: Metabolism and nutrition disorders: Rare: hyperglycaemia.
Maltese: Disturbi tal-qalb: Rari: takikardija.
English: Uncommon: pulmonary embolism, dyspnoea, pulmonary oedema, epistaxis, haemoptysis and hiccough.
Maltese: Mhux komuni: emboliżmu pulmonari, dispnea, edema pulmonari, tinfaraġ, emoptisi u sulluzzu.
English: Ciprofloxacin is potentially neurotoxic and causes reversible defects of the testes in case of higher dosage.
Maltese: Ciprofloxacin hu potenzjalment newrotossiku u jikkawża difetti riversibbli fit-testikoli f'każ ta' dożaġġ ogħla.